Company intelligence / Profile preview
HK inno.N Corporation
Seoul, South Koreainno-n.com ↗
- Ownership
- Private
- Employees
- ~1695
- Development stage
- Other
01
Overview
HK inno.N has successfully developed and commercialized K-CAB (tegoprazan), a novel potassium-competitive acid blocker (P-CAB) for GERD. It has become the #1 A2B product in the Korean market since its launch in 2019 and is expected to achieve $100M in sales in the Korean domestic market. The company has licensed the drug to partners in China and is conducting Phase 3 trials in the US and Canada through a partnership with Sebela Pharmaceuticals.
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Small moleculesBiopharmaceuticals
- Industry
- Biotech
02
Drug pipeline
36 assets35 more assets in the full pipeline.
03
Partnerships
Sebela Pharmaceuticals (US and Canada licensing for tegoprazan)Shandong Luoxin Pharmaceutical Group (China licensing)
Beyond the preview
Go deeper on HK inno.N Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HK inno.N Corporation.